Safety and effectiveness of recombinant factor XIII‐A(2) in congenital factor XIII deficiency: Real‐world evidence

BACKGROUND: Regular factor XIII (FXIII) prophylaxis is standard treatment for congenital FXIII A‐subunit deficiency (FXIII‐A CD). Recombinant factor XIII‐A(2) (rFXIII‐A(2)) was extensively evaluated in the mentor trials. OBJECTIVE: To assess real‐world safety and treatment effectiveness of rFXIII‐A(...

Descripción completa

Detalles Bibliográficos
Autores principales: Poulsen, Lone Hvitfeldt, Kerlin, Bryce A., Castaman, Giancarlo, Molinari, Angelo Claudio, Menegatti, Marzia, Nugent, Diane, Dey, Sohan, Garly, May‐Lill, Carcao, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882239/
https://www.ncbi.nlm.nih.gov/pubmed/35243202
http://dx.doi.org/10.1002/rth2.12628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882239/
https://www.ncbi.nlm.nih.gov/pubmed/35243202
http://dx.doi.org/10.1002/rth2.12628

Ejemplares similares